NCT05414149View on ClinicalTrials.gov

Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions
Proliferative Diabetic Retinopathy
Interventions
PROCEDURE

preoperative intravitreal injections of ranibizumab or conbercept

IVR group means patients received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery. IVC group means patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery.

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT05414149 - Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy | Biotech Hunter | Biotech Hunter